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INTRODUCTION
The use of large-volume databases in surgical out-
comes research has grown substantially over the last de-
cade, with surgeon, hospital, and regional-level outcomes 
increasingly being evaluated using clinical outcomes and 
measures of resource utilization.1–29 Large volume data-
bases can be broadly categorized as either administrative 
or clinical. These databases offer unique opportunities to 
study large-scale patterns of care, variation in practice, and 
outcomes following surgical intervention. Studies based 
on national registries and other administrative datasets 
have made significant contributions to the field of breast 
cancer surgery.1–24 In recent years, research derived from 
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Background: The aim was to assess reliability of the American College of Surgeons 
National Surgical Quality Improvement Program (ACS-NSQIP) 30-day periopera-
tive outcomes and complications for immediate, free-tissue transfer breast recon-
struction by direct comparisons with our 30-day and overall institutional data, and 
assessing those that occur after 30 days.
Methods: Data were retrieved for consecutive immediate, free-tissue transfer breast 
reconstruction patients from a single-institution database (2010–2015) and the 
ACS-NSQIP (2011–2014). Multiple logistic regressions were performed to com-
pare adjusted outcomes between the 2 datasets.
Results: For institutional versus ACS-NSQIP outcomes, there were no significant dif-
ferences in surgical-site infection (SSI; 30-day, 3.6% versus 4.1%, P = 0.818; overall, 
5.3% versus 4.1%, P = 0.198), wound disruption (WD; 30-day, 1.3% versus 1.5%, P 
= 0.526; overall, 2.3% versus 1.5%, P = 0.560), or unplanned readmission (URA; 30-
day, 2.3% versus 3.3%, P = 0.714; overall, 4.6% versus 3.3%, P = 0.061). However, the 
ACS-NSQIP reported a significantly higher unplanned reoperation (URO) rate (30-
day, 3.6% versus 9.5%, P < 0.001; overall, 5.3% versus 9.5%, P = 0.025). Institution-
al complications consisted of 5.3% SSI, 2.3% WD, 5.3% URO, and 4.6% URA, of 
which 25.0% SSI, 28.6% WD, 12.5% URO, and 7.1% URA occurred at 30–60 days, 
and 6.3% SSI, 14.3% WD, 18.8% URO, and 42.9% URA occurred after 60 days.
Conclusion: For immediate, free-tissue breast reconstruction, the ACS-NSQIP 
may be reliable for monitoring and comparing SSI, WD, URO, and URA rates. 
However, clinicians may find it useful to understand limitations of the ACS-NSQIP 
for complications and risk factors, as it may underreport complications occur-
ring beyond 30 days. (Plast Reconstr Surg Glob Open 2018;6:e1643; doi: 10.1097/
GOX.0000000000001643; Published online 6 March 2018.)
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these large data registries has played an increasing role in 
the development of clinical guidelines and health policy 
within the field of breast cancer treatment.1–24 One such 
validated large-volume clinical database is the American 
College of Surgeons National Surgical Quality Improve-
ment Program (ACS-NSQIP) database.30 Its validity hinges 
on the number of involved hospitals, accurate recording 
of key patient variables, and methodical follow-up to 30 
days postoperatively.31 This database has helped in multi-
ple areas within plastic surgery, including the recognition 
of risk factors for venous thromboembolism in breast re-
construction, the complications associated with contralat-
eral prophylactic mastectomy, and the impact of surgical 
resident involvement in breast reduction.15,17,23
Despite the versatility of the ACS-NSQIP database, 
several studies in multiple disciplines have questioned its 
validity, primarily in terms of the coding process and built-
in variables.32–37 Within plastic surgery, the ACS-NSQIP 
Surgical Risk Calculator has been assessed and deemed 
inaccurate for predicting risk factors for complications af-
ter breast reconstruction.32,33 Furthermore, the reported 
incidence of complications as defined by variables in the 
database has come under question, and by extension, the 
validity of the risk factors identified using the database.34–37 
These issues primarily stem from the question of whether 
30 days’ follow-up is sufficient to capture the full scope of 
complications. Recently published literature investigated 
the rate of complications occurring beyond 30 days in pa-
tients undergoing alloplastic breast reconstruction.34–36
Incidence and timing of complications were investigated 
by Luce et al.34 for tissue expander explantation and by Co-
hen et al.36 and Sinha et al.35 for infections in implants and tis-
sue expanders. In autologous breast reconstruction, Duraes 
et al.37 reported on the incidence of institutional late compli-
cations occurring after 30 days in abdominal-based free flap 
procedures. However, to date, there is a lack of literature on 
the presence and timing of complications in ACS-NSQIP for 
autologous breast reconstruction. To the best of our knowl-
edge, no previous studies have directly compared institu-
tional data with ACS-NSQIP to assess whether the national 
database is valid and applicable to institutional practice, 
within both the 30-day perioperative period or after 30 days.
Given this lack of knowledge, the aim of this study was 
to evaluate the reliability of the complications captured by 
the ACS-NSQIP within its early 30-day window for immedi-
ate, free-tissue breast reconstruction (IFTBR). This will be 
conducted by direct comparison of the outcomes reported 
in the ACS-NSQIP to both our 30-day and overall (compli-
cations that occur within 30 days and onward) institutional 
data, to determine whether the database is reliable for com-
plication monitoring and comparison studies. A secondary 
aim was to report the incidence and timing breakdown of 
late complications after autologous breast reconstruction, 
to determine whether ACS-NSQIP is reliable for a true over-
all complication profile and risk factor calculation studies.
METHODS
Institutional review board approval was obtained. Data 
were collected from patient records within a single insti-
tution from 2010 to 2015 with a minimum follow-up of 
1 year, and ACS-NSQIP data were retrieved for the years 
2011–2014 using Current Procedural Terminology (CPT) 
codes (see table, Supplementary Digital Content 1, which 
displays the CPT mastectomy and breast reconstruction 
codes, http://links.lww.com/PRSGO/A659). We extracted 
data from the respective time periods to account for as 
many possible data points for the variables of interest. Our 
inclusion criteria consisted of female patients over the age 
of 18 years who underwent IFTBR following mastectomy. 
We excluded patients who underwent combined free tis-
sue reconstruction with other autologous or alloplastic 
techniques. In ACS-NSQIP, a patient was considered to 
have undergone IFTBR if concurrent mastectomy and re-
construction CPT codes were registered.
Patient characteristics of interest were restricted to 
those recorded in both the institutional and ACS-NSQIP 
databases, to enable direct comparison. These included 
age, body mass index (BMI), smoking, diabetes, hyper-
tension, coagulopathy, steroid use, number of comorbidi-
ties, mastectomy type, operation time (OT) in minutes, 
and length of stay (LOS) in days. Bilateral mastectomy 
was determined based on the presence of 2 CPT codes 
for mastectomy. Outcomes of interest were surgical-site 
infection (SSI), wound disruption (WD), unplanned re-
operation (URO), unplanned readmission (URA), and 
the specific causes of URO or readmission. Before 2011, 
the ACS-NSQIP data did not include the cause of URO 
and URA variables. As such, URO and readmission data 
were extracted from ACS-NSQIP 2012–2014. Institutional 
complications were only recorded if they were related to 
the index IFTBR procedure and fit the ACS-NSQIP defini-
tions for SSI, WD, URO, and URA.
URO was classified into categories based on correlat-
ing ACS-NSQIP variables for the root cause, consisting of 
complications pertaining to the flap itself, SSI, wound-site 
disruption, hemorrhage, hematoma, and seroma. URA was 
classified into categories based on correlating ACS-NSQIP 
variables for the root cause, consisting of complications 
pertaining to the flap itself, SSI, wound-site disruption, 
hematoma, seroma, and postoperative pain. These were 
extracted from the ACS-NSQIP (2012–2014) using the in-
built reason for URO variable and International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification 
codes (see table, Supplementary Digital Content 2, which 
displays International Classification of Diseases, Ninth Re-
vision, Clinical Modification cause of URO or readmission 
codes, http://links.lww.com/PRSGO/A660).
Institutional outcomes in the 30-day window and over-
all, including both 30-day complications and those occur-
ring after 30 days, were each independently compared with 
ACS-NSQIP outcomes to assess reliability of the database. 
Late complications occurring after 30 days are represen-
tative of the number of complications potentially missed 
by ACS-NSQIP. Institutional outcomes were subgrouped 
into those that occurred within the 30-day window (early), 
those that occurred after 30 days (late), and the overall 
(early and late) complication incidence. In addition, com-
plications that occurred after 30 days were further subcat-
egorized into 60-day and 60-day+ groups.
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Statistical Analysis
Data were compared using Pearson’s χ2 or Fisher’s 
exact test tests and Wilcoxon-Mann-Whitney for categori-
cal and nonparametric continuous variables, respectively. 
To account and adjust for potential confounders when 
analyzing outcomes of interest, logistic regression models 
were used to assess patient outcomes of SSI, WD, URO, 
URA, and causes of URO or readmission. Statistical analy-
sis was performed using SPSS Version 22 (IBM, Armonk, 
N.Y.). For all analysis, a value of P < 0.05 was considered 
statistically significant.
RESULTS
Patient Characteristics
During the study period, a total of 2,402 patients were 
admitted for IFTBR, with 304 (12.6%) patients from our 
institution and 2,098 (87.3%) patients from the ACS-
NSQIP (2011–2014; Table 1). Patients were well matched 
for most patient characteristics. No significant differences 
were observed in age (P = 0.315), diabetes (P = 0.680), 
coagulopathy (P = 0.675), steroid use (P = 0.613), number 
of comorbidities (P = 0.350), LOS (P = 0.274), and pro-
portion of radical mastectomy (P = 0.114). Although the 
average patient in both was classified by BMI as “obese,” 
patients in our institution had a significantly lower BMI 
(28.2 ± 5.6 versus 29.9 ± 5.9 kg/m2, P < 0.001), longer OT 
(702.4 ± 166.9 versus 524.0 ± 182.3 minutes, P < 0.001), and 
underwent more bilateral (55.9% versus 40.2%, P < 0.001) 
and total simple mastectomies (96.7% versus 82.3%, 
P < 0.001) when compared with the ACS-NSQIP database. 
However, fewer patients in our institutional group were 
smokers (3.6% versus 8.9%, P = 0.002), had hypertension 
(18.4% versus 24.6%, P = 0.018), or underwent modi-
fied radical mastectomy (1.6% versus 14.0%, P < 0.001) 
compared with the ACS-NSQIP database. Patients in our 
institutional database underwent deep inferior epigastric 
perforator (96.2%), superior gluteal artery perforator 
(3.3%), and free transverse rectus abdominis myocutane-
ous (free TRAM) (0.2%) flap reconstructions, whereas 
this breakdown was not able to be assessed in the ACS-
NSQIP database.
Patient Outcomes (Institution Versus ACS-NSQIP)
Table 2 summarizes the adjusted patient outcomes 
for 30-day and overall institutional versus the ACS-NSQ-
IP, respectively. No significant differences were seen 
when comparing either institutional 30-day or overall 
complications to ACS-NSQIP outcomes for SSI (30-day, 
3.6% versus 4.1%, P = 0.818; overall, 5.3% versus 4.1%, 
P = 0.198), WD (30-day, 1.3% versus 1.5%, P = 0.526; 
overall, 2.3% versus 1.5%, P = 0.560), and URA (30-
day, 2.3% versus 3.3%, P = 0.714; overall, 4.6% versus 
3.3%, P = 0.061). However, there were significantly low-
er URO rates in our institutional data compared with 
ACS-NSQIP data (30-day, 3.6% versus 9.5%, P < 0.001; 
overall, 5.3% versus 9.5%, P = 0.025). Institutionally, 5 
(31.3%) of 16 UROs and 3 (21.4%) of 14 URAs were 
independent, with an overlap between UROs and read-
missions in the remaining 11 cases. In the ACS-NSQIP, 
136 (78.6%) of 173 UROs and 23 (38.3%) of 60 URAs 
were independent, with an overlap between UROs and 
readmissions in the remaining 37 cases. The discrep-
ancy may be due to some reoperations not necessarily 
necessitating a readmission, or vice versa, due to the 
ACS-NSQIP definition of an URA being for an “inpa-
tient” stay or an URO being performed within the same 
index inpatient stay.
URO (Institutional Versus ACS-NSQIP)
Reasons for URO are listed in Table 3. There were 
significantly fewer UROs reported in our institutional 
database compared with the ACS-NSQIP after selecting 
for specific complications (30-day, 3.6% versus 9.5%, 
P < 0.001; overall, 5.3% versus 9.5%, P = 0.025). Com-
pared with institutional data, there were a greater number 
of hematomas requiring URO in the ACS-NSQIP database 
(30-day, 1.0% versus 4.1%, P = 0.009; overall, 1.0% versus 
4.1%, P = 0.009).
Table 1. Institutional Versus the ACS-NSQIP Patient 
Characteristics
Patient Characteristics
Institutional ACS-NSQIP
Pn (%) n (%)
Total 304 (12.6) 2,098 (87.3)  
Age (y) 51.19 ± 9.14 50.55 ± 9.16 0.315
BMI (kg/m2) 28.2 ± 5.6 29.9 ± 5.9 < 0.001
Smoking 11 (3.6) 187 (8.9) 0.002
Diabetes 13 (4.3) 101 (4.8) 0.680
Hypertension 56 (18.4) 516 (24.6) 0.018
Coagulopathy 2 (0.7) 11 (0.5) 0.675
Steroid use 3 (1.0) 32 (1.5) 0.613
No. comorbidities     0.350
  0 233 (76.6) 1,531 (73.0) 0.176
  1 63 (20.7) 498 (23.7) 0.246
  ≥ 2 8 (2.6) 68 (3.2) 0.570
Mastectomy      
  Bilateral 170 (55.9) 844 (40.2) < 0.001
  Simple 294 (96.7) 1,726 (82.3) < 0.001
  Modified radical 5 (1.6) 293 (14.0) < 0.001
  Radical 2 (0.7) 44 (2.1) 0.114
  OT (min) 702.4 ± 166.9 524.0 ± 182.3 < 0.001
  Length of stay (d) 4.33 ± 1.41 4.64 ± 8.42 0.274
Bold type signifies p-value has reached statistical significance.
Table 2. Institutional (Total and ≤ 30 Days) Versus the ACS-
NSQIP Outcomes
Patient Outcomes
Institutional ACS-NSQIP
Pn (%) n (%)
SSI  
  Total 16 (5.3) 86 (4.1) 0.198
  30-d 11 (3.6) 86 (4.1) 0.818
WD      
  Total 7 (2.3) 31 (1.5) 0.560
  30-d 4 (1.3) 31 (1.5) 0.526
URO      
  Total 16 (5.3) 173* (9.5) 0.025
  30-d 11 (3.6) 173* (9.5) < 0.001
URA      
  Total 14 (4.6) 60† (3.3) 0.061
  30-d 7 (2.3) 60† (3.3) 0.714
*This value was determined after excluding any UROs not categorizable for 
comparison. It was extracted from ACS-NSQIP (2012–2014).
†This value was determined after excluding any URAs not categorizable for 
comparison. It was extracted from ACS-NSQIP (2012–2014).
Bold type signifies p-value has reached statistical significance.
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URA (Institutional Versus ACS-NSQIP)
Reasons for URA are listed in Table 4. There were 
no significant differences in URAs reported in our in-
stitutional database compared with the ACS-NSQIP after 
selecting for specific complications (30-day, 2.3% versus 
3.3%, P = 0.714; overall, 4.6% versus 3.3%, P = 0.061). 
The number of infections requiring URA occurring af-
ter 30 days was substantial enough to show a significantly 
higher rate in overall institutional versus the ACS-NSQIP 
data (30-day, 1.6% versus 1.8%, P = 0.850; overall, 3.3% 
versus 1.8%, P = 0.031).
Early Versus Late Complications (Institution)
In our institutional database, the complication profile 
consisted of 5.3% SSIs, 2.3% WDs, 5.3% UROs, and 4.6% 
URAs. Table 5 summarizes the percentage of these compli-
cations occurring after the 30 days. When observing what 
percentage of total complications were late, we found 
that 31.3% (25.0% by 30–60 days, 6.3% after 60 days) of 
SSIs, 42.9% of WDs (28.6% by 30–60 days, 14.3% after 60 
days), 31.3% of UROs (12.5% by 30–60 days, 18.8% after 
60 days), and 50.0% of URAs (7.1% by 30–60 days, 42.9% 
after 60 days) occurred after 30 days.
DISCUSSION
Large clinical databases such as the ACS-NSQIP serve 
as a unique platform for retrospective clinical studies, 
providing large patient populations suitable for studying 
outcomes and variations in treatment. Within the field of 
breast reconstruction, large-volume databases are being 
increasingly utilized.1–20 Studies based on clinical databas-
es have made significant contributions to the field of plas-
tic surgery with development of clinical guidelines and 
health policy. It is important for clinicians and researchers 
to understand the strengths and weaknesses of these data-
bases to enable appropriate data interpretation.19
The current study aims to assess the validity of the 
ACS-NSQIP database for IFTBR by comparing its reported 
incidence of complications to those reported in a reason-
ably high-volume academic center. Our results show that 
ACS-NSQIP may accurately represent the incidence of 
both 30-day and overall complications for SSI, WD, and 
URA, and as such be reliable for complication monitor-
ing and comparison studies. However, it did not accurately 
capture overall URAs due to infection. The ACS-NSQIP 
also reported a significantly higher rate of URO than that 
found in our institutional data, which was attributable to 
the higher rate of URO for hematoma. Although there 
were no significant differences between overall versus 
ACS-NSQIP complication rates, we found that a large per-
centage of SSIs, WDs, UROs, and URAs occur after the 30-
day window, suggesting that ACS-NSQIP may underreport 
complications. As such, it may not be reliable for studies 
evaluating true overall complication profiles or risk factor 
calculation.
URO rates were 1 important difference between in-
stitutional and ACS-NSQIP data, with ACS-NSQIP URO 
rates being significantly higher; this persisted when se-
lecting for IFTBR-specific complications. It may be that 
variation exists in institutional operative practices and de-
cision-making protocols for reoperation, explaining our 
findings. A study on autologous breast reconstruction con-
ducted using the National Inpatient Sample Healthcare 
Cost and Utilization Project has shown that high-volume 
centers have lower complications, with the volume-out-
come relationship being more strongly associated with 
surgery-specific rather than systematic complications.38 
The literature for microsurgical breast reconstruction has 
reported lower flap loss rates and improved salvage rates 
associated with tissue oximetry, with decreased rate of re-
exploration over time per 100 flaps operated on.39–42 The 
Table 3. Institutional (Total and ≤ 30 Days) Versus the ACS-
NSQIP (2012–2014) Categorized Unplanned Reoperations
Patient Outcomes
Institutional ACS-NSQIP
Pn (%) n (%)
URO      
  Total 16 (5.3) 173* (9.5) 0.025
  30-d 11 (3.6) 173* (9.5) < 0.001
Flap complication      
  Total 5 (1.6) 40 (2.2) 0.675
  30-d 5 (1.6) 40 (2.2) 0.675
Infection      
  Total 1 (0.3) 15 (0.8) 0.454
  30-d 0 (0.0) 15 (0.8) 0.994
WD      
  Total 6 (2.0) 41 (2.2) 0.887
  30-d 3 (1.0) 41 (2.2) 0.297
Hemorrhage      
  Total 1 (0.3) 5 (0.3) 0.865
  30-d 1 (0.3) 5 (0.3) 0.865
Hematoma      
  Total 3 (1.0) 75 (4.1) 0.009
  30-d 3 (1.0) 75 (4.1) 0.009
Seroma      
  Total 3 (1.0) 6 (0.3) 0.118
  30-d 2 (0.7) 6 (0.3) 0.393
*This value was determined after excluding any UROs not categorizable for 
comparison.
Bold type signifies p-value has reached statistical significance.
Table 4. Institutional (Total and ≤ 30 Days) Versus the ACS-
NSQIP (2012–2014) Categorized Unplanned Readmissions
Patient Outcomes
Institutional ACS-NSQIP
Pn (%) n (%)
URA      
  Total 14 (4.6) 60* (3.3) 0.061
  30-d 7 (2.3) 60* (3.3) 0.714
Flap complication      
  Total 1 (0.3) 6 (0.6) 0.526
  30-d 1 (0.3) 6 (0.6) 0.526
Infection      
  Total 10 (3.3) 33 (1.8) 0.031
  30-d 5 (1.6) 33 (1.8) 0.850
WD      
  Total 1 (0.3) 15 (0.8) 0.631
  30-d 0 (0.0) 15 (0.8) 0.994
Hematoma      
  Total 1 (0.3) 4 (0.2) 0.714
  30-d 1 (0.3) 4 (0.2) 0.714
Seroma      
  Total 1 (0.3) 1 (0.1) 0.204
  30-d 0 (0.0) 1 (0.1) 0.995
Postoperative pain      
  Total 1 (0.3) 2 (0.1) 0.806
  30-d 1 (0.3) 2 (0.1) 0.806
*This value was determined after excluding any UROs not categorizable for 
comparison.
Bold type signifies p-value has reached statistical significance.
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use of more than 1 venous outflow vessel may also prevent 
URO.43
When reviewing the causes for URO, hematoma ap-
peared to contribute to the higher rates of URO in ACS-
NSQIP, compared with institutional data. The lower rates 
found in our institutional data are supported by a previous 
review article outlining URO for hematomas in microvas-
cular free tissue transfers, noting rates ranging from 0.2% 
to 9%.44 Halle et al.45 reported a 13% incidence of reop-
erations for hematomas in breast free flaps, highlighting 
the potential risk of antithrombotic use and importance 
of using drains. A study assessing risk factors for hemato-
ma formation in 883 patients who underwent mastectomy 
and immediate reconstruction found no measurable pre-
operative, operative, or oncologic risk factors, citing that 
meticulous hemostasis may be 1 of the factors.46
It is important to note that a large percentage of SSIs, 
WDs, UROs, and URAs occurred after 30 days, highlight-
ing the possibility of an underreported complication rate 
in ACS-NSQIP. More specifically, the majority of SSIs and 
WDs occurred within 60 days, whereas the majority of 
UROs and URAs occurred after the 60-day period. This 
could be due to several temporal factors, including time 
taken for clinical deterioration sufficient to warrant URO 
or URA, or time required to arrange for patient hospital 
admission. All UROs and readmissions for flap complica-
tion, hemorrhage, or hematoma occurred within 30 days. 
The majority of UROs and readmissions for infection, se-
roma, and WD occurred after 30 days. It may be that the 
later reoperations and readmissions occurred as a result 
of managing conservatively at first for these complica-
tions. Furthermore, late management of seromas may be 
linked to the pathophysiology of seroma formation, which 
requires time for fluid collection. A study on abdominal-
based free tissue breast reconstruction complications 
by Duraes et al.37 also found that a large percentage of 
complications were late and inferred that the ACS-NSQIP 
30-day follow-up may not be sufficient. The percentages 
of early 30-day and late infection complications found in 
our data differed from those reported by Duraes et al.37 
(early, 68.8% versus 89.0%; late, 31.3% versus 11.0%). 
This finding may be due to the differing surgical teams, 
surgical technique, patient characteristics, or type of re-
construction. It may be prudent to extend the ACS-NSQIP 
follow-up period to up to 3 months, with further studies 
evaluating the optimum follow-up time for maximum cap-
ture of complications.
Studies have also reported a large percentage of late 
complications within alloplastic breast reconstruction, 
with Luce et al.34 reporting that 65% of tissue expanders 
destined for loss were still in situ at 30 days, Sinha et al.35 
reporting that 47–71% of SSIs were late (> 30 days), and 
Cohen et al.36 reporting that 50% of infections were late 
(> 30 days). Compared with these studies of alloplastic re-
construction, we found a lower rate of late complications. 
Similar findings were described by Mioton et al.47 in their 
report of 30-day complications, describing greater differ-
ences in autologous versus implant complications (infec-
tion, 5.46% versus 3.45%, P < 0.001; WD, 1.24% versus 
0.44%, P < 0.001; reoperation, 9.59% versus 6.76%, P < 
0.001). It may be interesting to assess the risk factors for 
early and late complications in autologous compared with 
implant reconstruction.
We acknowledge the limitations of our study. Retro-
spective chart reviews are at risk of human error in the 
data collection process. We were unable to assess certain 
parameters due to the presence of in-built variables in ACS-
NSQIP, including radiotherapy and chemotherapy. For fu-
ture reference, ACS-NSQIP may look to introduce these 
variables. We were also unable to subcategorize specific 
IFTBR procedures for comparison, such as deep inferior 
epigastric perforator, superior gluteal artery perforator, or 
free TRAM, due to limitations of CPT coding. The scope 
of the study was also limited to complications defined in 
ACS-NSQIP. As such, we could not analyze important out-
comes such as donor versus recipient complications, mas-
tectomy skin necrosis, fat necrosis, or abdominal hernia 
development. The inclusion of these variables may further 
surgical clinical outcomes’ research, with more targeted, 
inclusive data. Due to the single-center study comparison, 
and the uniqueness of the protocol at our high-volume 
center, this may have led to differences in the comparison 
of our outcomes versus those hospitals captured by the 
ACS-NSQIP, who may perform a lower number of free tis-
Table 5. Timing of Complications Breakdown (Institutional)
Patient Outcomes
Overall 30-d 60-d 60-d+
n (%) n (%) n (%) n (%)
SSI 16 (100.0) 11 (68.8) 4 (25.0) 1 (6.3)
WD 7 (100.0) 4 (57.1) 2 (28.6) 1 (14.3)
URO 16 (100.0) 11 (68.8) 2 (12.5) 3 (18.8)
Flap complication 5 (100.0) 5 (100.0) 0 (0.0) 0 (0.0)
Infection 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
WD 6 (100.0) 3 (50.0) 1 (16.7) 2 (33.3)
Hemorrhage 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0)
Hematoma 3 (100.0) 3 (100.0) 0 (0.0) 0 (0.0)
Seroma 3 (100.0) 2 (66.7) 0 (0.0) 1 (33.3)
URA 14 (100.0) 7 (50.0) 1 (7.1) 6 (42.9)
Flap complication 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0)
Infection 10 (100.0) 5 (50.0) 1 (10.0) 4 (40.0)
WD 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Hematoma 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0)
Seroma 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Postoperative pain 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0)
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sue breast reconstructions. Despite these, we believe that 
our study makes important contributions to the current 
literature, and to our knowledge, this is the first study to 
report a head-to-head comparison of outcomes between a 
single institution and a national database.
CONCLUSIONS
For complication monitoring and comparison studies, 
the ACS-NSQIP may reliably represent the general scope 
of SSIs, WDs, UROs, and URAs in institutional data for IF-
TBR; however, it may not generally capture URAs for infec-
tion occurring after 30 days. There was also a significantly 
higher rate of UROs for ACS-NSQIP, which was due to the 
differences in UROs for hematoma. A large percentage 
of complications in our institutional database occurred af-
ter 30 days, and as such, clinicians and researchers should 
continue to exercise caution when reporting overall com-
plication rates or assessing risk factors for future guide-
lines. An extension of the follow-up beyond 30 days should 
be considered.
Samuel J. Lin, MD, MBA
Division of Plastic and Reconstructive Surgery
Beth Israel Deaconess Medical Center
Harvard Medical School
110 Francis Street, Suite 5A
Boston, MA 02215
E-mail: sjlin@bidmc.harvard.edu
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